International Journal of Clinical Research

Objective To analyze the empirical value of clinical pharmacist participation in multidisciplinary treatment on the management of critically ill patients. Methods 120 critically ill patients admitted to our hospital from January 2025 to December 2025 were selected as the study subjects (covering critically ill cases from internal medicine, gynecology, obstetrics, pediatrics, and neonatology). They were divided into a control group and an observation group according to the treatment model, with 60 patients in each group. The control group adopted the conventional multidisciplinary treatment model, while the observation group adopted a multidisciplinary treatment model with full participation of clinical pharmacists (fully participating in consultations with gynecology, obstetrics, pediatrics, and the NICU of the neonatology department, and assisting in consultations with internal medicine and rehabilitation departments). The rationality of medication use, incidence of adverse reactions, length of hospital stay, length of stay in the ICU, mortality rate, and indicators related to antibiotic use were compared between the two groups. Results The rational drug use rate in the observation group was 93.33%, significantly higher than 76.67% in the control group (P<0.05); the incidence of adverse drug reactions in the observation group was 6.67%, lower than 20.00% in the control group (P<0.05); the length of hospital stay and ICU stay in the observation group were shorter than those in the control group (P<0.05); there was no statistically significant difference in mortality between the two groups (P>0.05); the duration of antibiotic use and the positive rate of bacterial culture in the observation group were lower than those in the control group (P<0.05). Conclusion The participation of clinical pharmacists in the multidisciplinary treatment model can significantly improve the rationality of medication use in critically ill patients, reduce the incidence of adverse drug reactions, shorten the length of hospital stay and ICU stay, and optimize the use of antibiotics. It is particularly suitable for the management of critically ill patients in our hospital's gynecology, obstetrics, pediatrics, neonatal intensive care unit (NICU), and internal medicine departments, and aligns with our hospital's actual clinical needs.

Clinical pharmacist; Multidisciplinary treatment model; Critically ill patients; Rational drug use